Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
52-week range
$0.01 – $3.42
11% from low
Exchange
OTC Link
CS
Borrow rate
13.15%
Hard to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross margin | — | — | — | — | — | — |
| R&D | $150.0K | $2.3M | $3.0M | $5.6M | $3.5M | $4.3M |
| Operating income | −$173.4K | −$3.6M | −$6.8M | −$11.8M | −$8.3M | −$9.2M |
| EBITDA | −$173.4K | −$30.2M | −$6.8M | −$11.7M | −$7.8M | −$7.7M |
| Net income | −$174.6K | −$30.3M | −$6.8M | −$11.7M | −$8.2M | −$8.5M |
| Net margin | — | — | — | — | — | — |
| EPS (diluted) | -0.01 | -1.30 | -0.29 | -0.47 | -0.32 | -0.25 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $17M | $-0.48 | $-0.48–$-0.48 | 1 |
| 2027 | $27M | $-0.46 | $-0.46–$-0.46 | 1 |
| 2028 | $79M | $-0.49 | $-0.49–$-0.49 | 1 |
| 2029 | $0 | $-0.54 | $-0.54–$-0.54 | 1 |
Forward consensus · source: Financial Modeling Prep
ANEBULO PHARMAC INC
No one on the platform currently holds ANEB.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-12-31 | 25,098 | $25.3K |
No one on the platform has traded ANEB yet.
| $571M |
| — |
| MGNXMacroGenics, Inc. | $4.86 | +1.04% | $309M | — |
| OKYOOKYO Pharma Limited | $1.52 | -1.94% | $58M | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
Whiskey Penny Picks out tomorrow. Any great cheap oil, defense/drone type stocks? Hit me up!! Might pick 'em tomorrow morning!! AH Gainers/trending a bit: $ELPW $LRHC $ANEB $INUV $BGL
View on StockTwits ↗$ANEB confirmed, delisted this Monday. to quote in OTC
View on StockTwits ↗$ANEB Anebulo Pharmaceuticals develops addiction therapies. Clinical milestones drive valuation. Early-stage risk remains.
View on StockTwits ↗$ANEB - Anebulo Pharmaceuticals, Inc. - 10Q - Updated Risk Factors ANEB flags ongoing zero revenue, a $78M accumulated deficit, rising R&D spend for clinical trials, and uncertainty about securing funding, warning it may need to scale back operations and may never reach profitability even after going private. #Pharmaceuticals #R&DSpending #FinancialRisk #FundingUncertainty #OperationalScaling 🟢 Added 🟠 Removed https://d-risk.ai/ANEB/10-Q/2026-02-12
View on StockTwits ↗$ANEB Biotech or pharmaceutical; name not standard, indicating high risk.
View on StockTwits ↗@Hatim1979 ian't this partgo pri.... it's being held by alot of tutes? $ANEB
View on StockTwits ↗$ANEB Anebulo Pharmaceuticals will voluntarily delist its common stock from the Nasdaq Stock Market, effective February 27, 2026, after its number of shareholders fell below 300. The decision was officially announced on February 6, 2026, and will terminate the company’s reporting obligations with the U.S. Securities and Exchange Commission (SEC).
View on StockTwits ↗$ANEB what's everyone's take on the buyout price to go private...... Debating whether i should take a position here before it goes to the otc
View on StockTwits ↗$ANEB have they communicated a buyout ricgorivate?
View on StockTwits ↗$ADAPY $ANEB completely different situation
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.